Clincosm LogoSign in Get a demo

classical hodgkin lymphoma

Showing 1 - 25 of 41
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Classical Hodgkin Lymphoma, Non-Hodgkin Lymphoma Trial (GEN3017)

Not yet recruiting
  • Classical Hodgkin Lymphoma
  • Non-Hodgkin Lymphoma
  • GEN3017
  • (no location specified)
Aug 25, 2023

Classical Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL) Trial in

Not yet recruiting
  • Classical Hodgkin Lymphoma
  • +2 more
  • Lifestyles Implemented-Survivorship Care Plan (LS-SCP)
  • Ancona, Italy
  • +39 more
Jun 28, 2023

Classical Hodgkin Lymphoma Trial in Guangzhou (Zimberelimab 240mg)

Recruiting
  • Classical Hodgkin Lymphoma
  • Zimberelimab 240mg
  • Guangzhou, Guangdong, China
    Department of Medical Oncology, Sun Yat-Sen University Cancer Ce
Jun 15, 2023

Advanced Cancer, Advanced Solid Tumor, Tumor Malignant Trial in United Kingdom (Fosifloxuridine Nafalbenamide, Leucovorin,

Not yet recruiting
  • Advanced Cancer
  • +16 more
  • Fosifloxuridine Nafalbenamide
  • +3 more
  • Birmingham, United Kingdom
  • +3 more
Feb 1, 2023

NSCLC, Gastric Carcinoma, Gastroesophageal Junction Carcinoma Trial in Worldwide (SEA-TGT, sasanlimab)

Recruiting
  • Non-small Cell Lung Cancer
  • +11 more
  • Birmingham, Alabama
  • +32 more
Jan 4, 2023

Melanoma, Lymphoma, Solid Tumor Trial in Worldwide (Pembrolizumab)

Recruiting
  • Melanoma
  • +4 more
  • Pembrolizumab
  • Aurora, Colorado
  • +18 more
Jan 5, 2023

Classical Hodgkin Lymphoma Trial in Worldwide (Tislelizumab)

Active, not recruiting
  • Classical Hodgkin Lymphoma
  • Detroit, Michigan
  • +34 more
Dec 29, 2022

Classical Hodgkin Lymphoma Trial in Philadelphia (Itacitinib, Everolimus)

Active, not recruiting
  • Classical Hodgkin Lymphoma
  • Philadelphia, Pennsylvania
    Abramson Cancer Center of the University of Pennsylvania
Nov 28, 2022

Classical Hodgkin Lymphoma Trial in Seattle (drug, other, biological)

Recruiting
  • Classical Hodgkin Lymphoma
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Sep 8, 2022

Leukemia, Acute Myeloid, MDS, Classical Hodgkin Lymphoma Trial in United States (MGD024)

Recruiting
  • Leukemia, Acute Myeloid
  • +7 more
  • Denver, Colorado
  • +4 more
Aug 29, 2022

Elderly Classical Hodgkin Lymphoma Undergoing CGA at Diagnosis

Recruiting
  • Classical Hodgkin Lymphoma
  • Treatment for clinical practise
  • Alessandria, Italy
  • +43 more
Aug 23, 2022

Melanoma, Non-small Cell Lung Carcinoma (NSCLC), Renal Cell Carcinoma (RCC) Trial in Gainesville, Jacksonville (LITT +

Recruiting
  • Melanoma
  • +14 more
  • LITT + Pembrolizumab
  • Gainesville, Florida
  • +1 more
Aug 22, 2022

Classical Hodgkin Lymphoma Trial in Cologne (Pembrolizumab plus Chemotherapy (ICE or DHAP))

Not yet recruiting
  • Classical Hodgkin Lymphoma
  • Pembrolizumab plus Chemotherapy (ICE or DHAP)
  • Cologne, Germany
    1st Department of Medicine, Cologne University Hospital
Aug 5, 2022

Classical Hodgkin Lymphoma Trial in Cologne (Nivolumab, Adriamycin, Vinblastine)

Active, not recruiting
  • Classical Hodgkin Lymphoma
  • Cologne, Germany
    University Hospital of Cologne
Aug 5, 2022

Classical Hodgkin Lymphoma Trial in Cologne (Tislelizumab)

Not yet recruiting
  • Classical Hodgkin Lymphoma
  • Cologne, Germany
    1st Department of Medicine, Cologne University Hospital
Aug 5, 2022

Classical Hodgkin Lymphoma Trial in Charlottesville (Pembrolizumab, Doxorubicin, Vinblastine)

Recruiting
  • Classical Hodgkin Lymphoma
  • Charlottesville, Virginia
    University of Virginia
Jul 27, 2022

Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type, Classical Hodgkin Lymphoma Trial in Houston (CD30.CAR-EBVST cells)

Recruiting
  • Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type
  • Classical Hodgkin Lymphoma
  • CD30.CAR-EBVST cells
  • Houston, Texas
  • +1 more
Jul 20, 2022

Classical Hodgkin Lymphoma, Hodgkin Disease Refractory, Hodgkin Disease Recurrent Trial in United States (Nivolumab, Autologous

Recruiting
  • Classical Hodgkin Lymphoma
  • +2 more
  • Duarte, California
  • +4 more
Jun 27, 2022

Classical Hodgkin Lymphoma, Refractory or Relapsed Classical Hodgkin Lymphoma Trial in Guangzhou (PD-1 inhibitor, PD-1

Recruiting
  • Classical Hodgkin Lymphoma
  • Refractory or Relapsed Classical Hodgkin Lymphoma
  • PD-1 inhibitor
  • PD-1 inhibitor, gemcitabine, vinorelbine and doxorubicin liposome
  • Guangzhou, Guangdong, China
  • +2 more
May 6, 2022

Lung Tumors, NSCLC, Carcinoma, Small Cell Trial in Worldwide (CK-301 (cosibelimab))

Recruiting
  • Lung Neoplasms
  • +12 more
  • CK-301 (cosibelimab)
  • Wollongong, New South Wales, Australia
  • +47 more
Mar 3, 2022

Immune Responses to COVID-19 Vaccination in Lymphoma Patients

Active, not recruiting
  • Classical Hodgkin Lymphoma
  • +12 more
    • Bedford, Bedfordshire, United Kingdom
    • +8 more
    Feb 22, 2022

    Classical Hodgkin Lymphoma Trial in China (Tislelizumab, Salvage Chemotherapy)

    Recruiting
    • Classical Hodgkin Lymphoma
    • Beijing, Beijing, China
    • +6 more
    Jan 4, 2022

    Classical Hodgkin Lymphoma, Relapsed Cancer, Refractory Cancer Trial in Toronto (Pembrolizumab, Bendamustine Hydrochloride)

    Recruiting
    • Classical Hodgkin Lymphoma
    • +2 more
    • Toronto, Ontario, Canada
      Princess Margaret Cancer Centre
    Dec 31, 2021

    Classical Hodgkin Lymphoma Trial in China (Tislelizumab)

    Completed
    Has Results
    • Classical Hodgkin Lymphoma
    • Beijing, Beijing, China
    • +10 more
    Oct 18, 2021

    Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma, Classical Hodgkin Lymphoma Trial in Atlanta (Bendamustine, Gemcitabine,

    Active, not recruiting
    • Recurrent Hodgkin Lymphoma
    • +3 more
    • Atlanta, Georgia
    • +1 more
    Aug 25, 2021